Prokarium to present at the Annual European Association of Urology (EAU) Congress

Prokarium’s CEO, Ibs Mahmood, will be presenting at the 41st Annual EAU Congress, London, UK, 13-16th March 2026.

Presentation information:

  • Presentation Title: PARADIGM 1 – A multi-center Phase 1 study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first interim review (Abstract ID: A0089)
  • Session Title: High-risk NMIBC: Evolving BCG–immunotherapy strategies and technical advances in TURB (Abstract Session 05)
  • Session Date and Time: Friday 13th March, 16:20 – 16:56

Related News

London, UK – 16 February 2026 – Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment...
London, UK – November 11, 2025 – Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced  the...
London, UK – November 11, 2025 – Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced  the...
LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...
LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...